Table 2.
Cancer diagnosis and treatment characteristics of Sister Study and Two Sister Study participants who were employed at breast cancer diagnosis and completed the Survivorship Survey (n = 1628), overall and by employment disruption and financial hardship
| Characteristic | Overall | No employment disruption | Employment disruption | No financial hardship | Financial hardship |
|---|---|---|---|---|---|
| Total No. | 1628 | 1184 | 444 | 1286 | 342 |
| Median age at cancer diagnosis (IQR), y | 48.2 (9.8) | 48.4 (10.2) | 47.7 (9.4) | 48.5 (10.6) | 46.8 (6.9) |
| Age at cancer diagnosis, No. (%)a | |||||
| 28 to <40 y | 125 (7.7) | 84 (7.1) | 41 (9.2) | 84 (6.5) | 41 (12.0) |
| 40 to <50 y | 943 (57.9) | 679 (57.3) | 264 (59.5) | 738 (57.4) | 205 (59.9) |
| 50 to <60 y | 335 (20.6) | 253 (21.4) | 82 (18.5) | 275 (21.4) | 60 (17.5) |
| 60-80 y | 225 (13.8) | 168 (14.2) | 57 (12.8) | 189 (14.7) | 36 (10.5) |
| Cancer stage, No. (%)a | |||||
| Stage 0 (in situ) | 308 (19.0) | 266 (22.5) | 42 (9.5) | 265 (20.7) | 43 (12.6) |
| Stages I-II | 1,138 (70.1) | 812 (68.8) | 326 (73.4) | 899 (70.1) | 239 (70.1) |
| Stages III-IV | 178 (11.0) | 102 (8.6) | 76 (17.1) | 119 (9.3) | 59 (17.3) |
| Missing | 4 (0.2) | 4 (0.3) | 0 (0) | 3 (0.2) | 1 (0.3) |
| Cancer treatment, No. (%)a | |||||
| Surgery only | 273 (16.8) | 215 (18.2) | 58 (13.1) | 233 (18.1) | 40 (11.7) |
| Radiation with no chemotherapy | 440 (27.0) | 375 (31.7) | 65 (14.6) | 373 (29.0) | 67 (19.6) |
| Any chemotherapy | 913 (56.1) | 593 (50.1) | 320 (72.1) | 679 (52.8) | 234 (68.4) |
| No surgery, radiation, or chemotherapy | 1 (0.06) | 0 (0) | 1 (0.2) | 0 | 1 (0.3) |
| Missing | 1 (0.06) | 1 (0.08) | 0 (0) | 1 (0.08) | 0 (0) |
| Time since last surgery, radiation, or chemotherapy, No. (%)a | |||||
| Currently receiving treatment | 38 (2.4) | 17 (1.5) | 21 (4.8) | 18 (1.4) | 20 (6.0) |
| <12 months | 115 (7.2) | 80 (6.9) | 35 (8.0) | 92 (7.3) | 23 (6.8) |
| 1 to <5 years | 760 (47.4) | 543 (46.6) | 217 (49.4) | 583 (46.0) | 177 (52.7) |
| 5+ years | 690 (43.0) | 524 (45.0) | 166 (37.8) | 574 (45.3) | 116 (34.5) |
| Missing | 25 (1.5) | 20 (1.7) | 5 (1.1) | 19 (1.5) | 6 (1.8) |
| Treatment effects, No. (%)a | |||||
| Yesb | 612 (38.6) | 385 (33.2) | 227 (53.3) | 438 (35.0) | 174 (52.4) |
| Lymphedema | 271 (16.7) | 163 (13.8) | 108 (24.6) | 183 (14.3) | 88 (26.0) |
| Neuropathy | 303 (19.0) | 173 (14.8) | 130 (30.4) | 210 (16.6) | 93 (28.4) |
| Heart disease | 63 (3.9) | 33 (2.8) | 30 (6.9) | 45 (3.5) | 18 (5.3) |
| Osteoporosis | 171 (10.6) | 110 (9.4) | 61 (13.9) | 123 (9.7) | 48 (14.2) |
| No | 972 (61.4) | 773 (66.8) | 199 (46.7) | 814 (65.0) | 158 (47.6) |
| Missing | 44 (2.7) | 26 (2.2) | 18 (4.1) | 34 (2.6) | 10 (2.9) |
a
Nonmissing observations: percentage of nonmissing observations; missing observations: percentage of all observations. IQR = interquartile range.
b
Categories are not mutually exclusive.